日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema

索西柏西普抑制血管内皮生长因子C和D联合阿柏西普治疗糖尿病性黄斑水肿的1b期剂量递增研究

期刊:Translational Vision Science & Technology
影响因子:2.6
doi:10.1167/tvst.13.12.32
Boyer, David S; Steinle, Nathan C; Pearlman, Joel A; Stone, Cameron M; Crawford, Courtney; Gupta, Sunil; Dugel, Pravin U; Baldwin, Megan E; Leitch, Ian M
糖尿病
心血管
代谢
发表日期：2024
文献求助 收藏

Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema

THR-687（一种新型高效整合素拮抗剂）治疗糖尿病性黄斑水肿的I期临床研究

期刊:Ophthalmology Science
影响因子:4.6
doi:10.1016/j.xops.2021.100040
Khanani, Arshad M; Patel, Sunil S; Gonzalez, Victor H; Moon, Suk J; Jaffe, Glenn J; Wells, John A; Kozma, Petra; Dugel, Pravin U; Maturi, Raj K
代谢
糖尿病
发表日期：2021
文献求助 收藏

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

血浆激肽释放酶抑制剂THR-149治疗糖尿病性黄斑水肿的I期剂量递增研究

期刊:Translational Vision Science & Technology
影响因子:2.6
doi:10.1167/tvst.10.14.28
Dugel, Pravin U; Khanani, Arshad M; Berger, Brian B; Patel, Sunil; Fineman, Mitchell; Jaffe, Glenn J; Kozma-Wiebe, Petra; Heier, Jeffrey
糖尿病
代谢
发表日期：2021
文献求助 收藏

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial

法瑞西单抗与雷珠单抗不同剂量和治疗方案在新生血管性年龄相关性黄斑变性中的安全性和有效性：AVENUE II期随机临床试验

期刊:Jama Ophthalmology
影响因子:9.2
doi:10.1001/jamaophthalmol.2020.2685
Sahni, Jayashree; Dugel, Pravin U; Patel, Sunil S; Chittum, Mark E; Berger, Brian; Del Valle Rubido, Marta; Sadikhov, Shamil; Szczesny, Piotr; Schwab, Dietmar; Nogoceke, Everson; Weikert, Robert; Fauser, Sascha
AVEN
发表日期：2020
文献求助 收藏

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial

法瑞西单抗每四个月和每季度给药与雷珠单抗治疗新生血管性年龄相关性黄斑变性的疗效比较：STAIRWAY II期随机临床试验

期刊:Jama Ophthalmology
影响因子:9.2
doi:10.1001/jamaophthalmol.2020.2699
Khanani, Arshad M; Patel, Sunil S; Ferrone, Philip J; Osborne, Aaron; Sahni, Jayashree; Grzeschik, Susanna; Basu, Karen; Ehrlich, Jason S; Haskova, Zdenka; Dugel, Pravin U
发表日期：2020
文献求助 收藏

Economic Value of Anti-Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States

美国抗血管内皮生长因子治疗湿性年龄相关性黄斑变性患者的经济价值

期刊:Jama Ophthalmology
影响因子:9.2
doi:10.1001/jamaophthalmol.2019.4557
Mulligan, Karen; Seabury, Seth A; Dugel, Pravin U; Blim, Jill F; Goldman, Dana P; Humayun, Mark S
心血管
发表日期：2020
文献求助 收藏

ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA: An Independent Analysis of Protocol i Study Data

早期血管内皮生长因子抗治疗的解剖学反应与糖尿病性黄斑水肿长期预后之间的关联：一项基于Protocol i研究数据的独立分析

期刊:Retina-The Journal of Retinal and Vitreous Diseases
影响因子:2.1
doi:10.1097/IAE.0000000000002110
Dugel, Pravin U; Campbell, Joanna H; Kiss, Szilárd; Loewenstein, Anat; Shih, Vanessa; Xu, Xiaoshu; Holekamp, Nancy M; Augustin, Albert J; Ho, Allen C; Gonzalez, Victor H; Whitcup, Scott M
心血管
代谢
糖尿病
发表日期：2019
文献求助 收藏

THE OASIS MP-1 SUBSTUDY: Characterization of the Effect of Ocriplasmin on Microperimetry Parameters

OASIS MP-1 子研究：Ocriplasmin 对微视野参数影响的特征分析

期刊:Retina-The Journal of Retinal and Vitreous Diseases
影响因子:2.1
doi:10.1097/IAE.0000000000001982
Sadda, SriniVas R; Dugel, Pravin U; Gonzalez, Victor H; Meunier, Esmeralda; Kozma, Petra
发表日期：2019
文献求助 收藏

CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA

糖尿病性黄斑水肿多因素性质的临床证据

期刊:Retina-The Journal of Retinal and Vitreous Diseases
影响因子:2.1
doi:10.1097/IAE.0000000000001555
Chakravarthy, Usha; Yang, Yit; Lotery, Andrew; Ghanchi, Faruque; Bailey, Clare; Holz, Frank G; Downey, Louise; Weber, Michel; Eter, Nicole; Dugel, Pravin U
代谢
糖尿病
发表日期：2018
文献求助 收藏

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2)

抗 VEGF 治疗视网膜静脉阻塞相关黄斑水肿：临床实践中的使用模式和有效性（ECHO 研究报告 2）

期刊:Clinical Ophthalmology
影响因子:1.8
doi:10.2147/OPTH.S163859
J Michael Jumper, Pravin U Dugel, Sanford Chen, Kevin J Blinder, John G Walt
信号转导
发表日期：2018
文献求助 收藏